Precision BioSciences (DTIL) AI Stock Analysis

• Market Cap: $88.69M
• Dividend Yield: N/A
• Average Volume (3M): 123.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.09
• Revenue Growth: -99.07%
• EPS Growth: -10347.56%
• Country: US
• Employees: 108
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.84
• Shares Outstanding: 13,256,751
• 10 Day Avg. Volume: 185,671
• 30 Day Avg. Volume: 123,923
• PEG Ratio: -0.03
• Price to Book (P/B): 0.46
• Price to Sales (P/S): 0.38
• P/FCF Ratio: -0.44
• Enterprise Value/Market Cap: 0.15
• Enterprise Value/Revenue: 19.48
• Enterprise Value/Gross Profit: -20.23
• Enterprise Value/Ebitda: -0.17
• 1Y Price Target: $45.00
• Price Target Upside: 632.90% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $6.00 ▼(-2.28% Downside)

The overall stock score is primarily impacted by the company's poor financial performance, characterized by declining revenues and significant losses. Technical analysis provides a slightly more positive outlook with some bullish momentum, but valuation remains a concern due to the negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Proprietary Technology

The ARCUS genome editing platform is a key competitive advantage, enabling precise DNA edits for innovative therapies, supporting long-term growth.

Strategic Partnerships

Strategic partnerships provide funding and development support, enhancing Precision BioSciences' ability to advance its therapeutic pipeline and sustain operations.

Improved Leverage

Improved leverage indicates better financial management, reducing risk and potentially enhancing the company's ability to invest in growth opportunities.

Negative Factors

Declining Revenues

Sharp decline in sales suggests challenges in market demand or competitive positioning, impacting long-term revenue sustainability and growth prospects.

Negative Profit Margins

Substantial losses relative to revenue indicate ongoing profitability challenges, which can hinder investment in R&D and future growth initiatives.

Negative Cash Flow

Negative cash flow highlights financial strain, limiting the company's ability to fund operations and invest in new projects without external financing.

Precision BioSciences Business Overview & Revenue Model

Company Description

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

How the Company Makes Money

Precision BioSciences generates revenue through a combination of partnerships, collaborations, and licensing agreements. The company often enters into strategic alliances with pharmaceutical companies to co-develop therapies, which can provide upfront payments, research funding, and milestone payments as specific development goals are achieved. Additionally, Precision BioSciences may receive royalties on future product sales resulting from these collaborations. The company also pursues grant funding and may generate revenue from its proprietary technology through licensing deals, allowing others to utilize its ARCUS genome editing platform in their own research and development efforts.

Precision BioSciences Financial Statement Overview

Summary

Precision BioSciences faces significant financial challenges, particularly in terms of revenue decline and profitability. While the balance sheet shows low leverage, the negative return on equity and cash flow issues highlight ongoing financial instability. The company needs to address its revenue and profitability issues to improve its financial health.

Income Statement

Precision BioSciences has experienced a significant decline in revenue, with a TTM revenue growth rate of -97.53%. The company also shows negative net profit and EBIT margins, indicating ongoing profitability challenges. Despite a high gross profit margin, the overall financial health of the income statement is weak due to substantial losses.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio of 0.041 in the TTM period, suggesting manageable leverage. However, the return on equity is negative, reflecting poor profitability. The equity ratio is not provided, but the overall balance sheet stability is moderate given the low leverage.

Cash Flow

The cash flow statement reveals a negative operating cash flow and free cash flow, with a slight improvement in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	698.00K	68.70M	48.73M	25.10M	115.53M	24.29M
Gross Profit	-672.00K	68.70M	48.73M	25.10M	115.53M	24.29M
EBITDA	-79.30M	13.53M	-32.04M	-62.79M	-20.27M	-99.19M
Net Income	-83.60M	7.17M	-61.32M	-111.64M	-30.60M	-109.01M
Balance Sheet
Total Assets	93.51M	136.39M	159.78M	238.17M	211.50M	150.16M
Cash, Cash Equivalents and Short-Term Investments	44.87M	86.31M	116.68M	189.58M	143.66M	89.80M
Total Debt	29.13M	30.05M	31.27M	24.96M	9.11M	10.52M
Total Liabilities	76.88M	80.00M	140.92M	177.74M	120.33M	105.73M
Stockholders Equity	16.63M	56.39M	18.86M	60.43M	91.17M	44.42M
Cash Flow
Free Cash Flow	-73.69M	-58.70M	-86.39M	-49.07M	-16.66M	-92.42M
Operating Cash Flow	-73.28M	-58.45M	-84.11M	-45.75M	-10.85M	-87.39M
Investing Cash Flow	-406.00K	-215.00K	5.83M	-3.32M	-5.80M	-5.03M
Financing Cash Flow	23.57M	50.45M	5.39M	94.98M	70.52M	1.33M

Precision BioSciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.14
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Neutral. The current price of 6.14 is below the 20-day moving average (MA) of 7.01, above the 50-day MA of 5.87, and above the 200-day MA of 5.16, indicating a neutral trend. The MACD of 0.28 indicates Positive momentum. The RSI at 43.32 is Neutral, neither overbought nor oversold. The STOCH value of 9.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DTIL.

Precision BioSciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	70 Outperform	$694.28M	7.33	108.21%	―	18.01%	306.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLUE	51 Neutral	―	―	―	―	127.51%	56.94%
DTIL	46 Neutral	$88.69M	-0.80	-205.16%	―	-99.07%	-10347.56%
IMA	41 Neutral	$92.14M	-1.08	-23.76%	―	-100.00%	55.32%
ACRV	36 Underperform	$62.91M	―	-47.87%	―	―	18.86%
ACET	27 Underperform	$105.79M	-0.53	-71.73%	―	―	25.89%

Precision BioSciences Corporate Events

Precision BioSciences Reports Q3 2025 Financial Results

Precision BioSciences, Inc. is a clinical-stage gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet needs. The company recently announced its third-quarter 2025 financial results, highlighting significant progress in its gene editing pipeline, particularly with its PBGENE-HBV and PBGENE-DMD programs.

Precision BioSciences Advances with Promising Hepatitis B Gene-Editing Study

Precision BioSciences is conducting a Phase 1 study titled ‘A Phase 1, Open-Label, First-in-Human, Dose Escalation (Part 1) and Expansion (Part 2) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of PBGENE-HBV in Participants With Chronic Hepatitis B (ELIMINATE-B).’ The study aims to assess the safety, tolerability, pharmacokinetics, and antiviral activity of PBGENE-HBV, a novel gene-editing intervention for chronic hepatitis B.

Precision BioSciences Updates Executive Employment Agreements

On August 26, 2025, Precision BioSciences amended and restated employment agreements for its key executives to retain them and reflect updated compensation terms. These agreements include provisions for termination without cause and require funding of severance and expenses in an escrow account, with interest and unused funds benefiting the company.

The most recent analyst rating on (DTIL) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Precision BioSciences Reports Significant Quarterly Loss

Precision BioSciences, Inc., a biotechnology company specializing in gene editing technologies, focuses on developing in vivo therapies for genetic and infectious diseases using its proprietary ARCUS genome editing platform. In its latest earnings report for the quarter ending June 30, 2025, Precision BioSciences reported a significant net loss of $23.5 million, a notable decline from the $32.7 million net income reported in the same quarter of the previous year. The company’s revenue also saw a sharp decrease, with only $18,000 reported for the quarter compared to $49.9 million in the previous year. This downturn is attributed to the termination of certain agreements and a strategic shift to focus solely on in vivo gene editing therapies. Despite the financial challenges, the company continues to invest in research and development, with expenses totaling $12.8 million for the quarter. Looking ahead, Precision BioSciences remains committed to advancing its ARCUS platform and exploring new collaborations to support its strategic focus on gene editing therapies.